Breakthrough innovations have come to light that have proved to be more than 95% effective in preventing HIV infection with injections just twice a year. Once a year might even be possible. They could also be key for 40 million people living with HIV around the world who need better options for trea...tment. It’s not a cure or a vaccine, but it could be a game-changer if made accessible to all who could benefit.
more
The purpose of this field guide is to provide comprehensive information on planning and implementing high-quality3 SIAs for injectable vaccines and highlight the opportunities to strengthen RI and surveillance. The guide uses measles–rubella SIAs as the main example throughout, but the informatio...n provided aims to be applicable to SIAs delivering any injectable vaccine. It can serve as a reference for the preparation of regional/national SIA field guides and materials.
more
The 2007 Rwanda Service Provision Assessment (RSPA) was a national representative survey conducted in 538 health facilities throughout Rwanda. The survey covered hospitals, health centers, dispensaries and
health posts, including all public facilities such as government and government-assisted heal...th facilities. The 2007 RSPA used interviews with health service providers and clients and observations of provider client consultations to obtain information on the capacity of facilities to provide quality services and the existence of functioning systems to support quality services. The areas addressed were the overall facility
infrastructure, maternal and child health, reproductive health, tuberculosis, malaria services; and services for sexually transmitted infections and HIV/AIDS. The objective was to assess the strengths and
weaknesses of the infrastructure and systems supporting these services, and to assess the adherence to standards in the delivery of services.
more
Over the past 50 years, dengue has spread from nine to over a hundred countries, making it the most rapidly spreading vector-borne disease. Yet, dengue continues to have a low profile among policy-makers and donors and does not receive the media attention it deserves. While there is no vaccine or cu...re for dengue, it can be managed and prevented. We need a renewed commitment to integrated programming that includes improved management and diagnosis, increased awareness and community participation in controlling the vector and enhanced environmental sanitation
more
The objective of this concept note and the framework it outlines is the elimination of a group of CDs and the negative health effects they generate, which together create a tangible burden on affected individuals, their families and communities, and on health care systems throughout the Region. Thou...gh there is no unified consensus on the best measures to use for the public’s health and a nation’s epidemiologic situation, it is common for the disease burden to be measured by disease rates (incidence, prevalence, etc.), disease-specific death rates, comparative morbidity and mortality rates, geographic distribution, and disability-adjusted life years (DALYs). The current epidemiological situation, including data on disease rates or geographic distribution for the diseases in Table 1, is discussed below in Section 4. Hotez et al. (2008) were the first to review and compare the burden of DALYs in Latin America and the Caribbean—for NTDs, HIV/AIDS, malaria, and TB—as it existed about 10 years ago. Though the regional burden of TB, malaria, and neglected infectious diseases (NIDs) is somewhat less than it was 10 years ago, work (and schooling) continue to be lost to illness and premature death or disability, and the need for stepping up disease elimination efforts is evident in all communities living in vulnerable conditions....
more
Brève introduction: Formation au vaccin contre le paludisme. Pour les pays planifiant l’introduction du vaccin contre le paludisme, l’OMS a développé des trousses de formation comprenant des séries de diapositives en anglais et en français sur des sujets clés destinés aux agents de santé..., qui peuvent être téléchargés et adaptées pour répondre aux besoins spécifiques des pays
more
Programa de Implementação da Vacina contra a Malária: 2019 – 2023.
The AHO Malaria Fact Sheet gives a brief overview of malaria as a preventable and curable disease caused by Plasmodium parasites, mainly affecting sub-Saharan Africa. It highlights symptoms like fever and chills, notes vulnerable groups such as young children and pregnant women, and emphasizes the n...eed for targeted prevention and treatment.
more
This video explores the impact of rapid urbanisation on the transmission of malaria, highlighting that, although the burden of malaria remains highest in rural areas, the majority of people in malaria-endemic countries will soon reside in urban areas. It explains how well-planned urbanisation can re...duce malaria by improving access to healthcare and infrastructure, whereas rapid, unplanned urban growth may increase the risk, particularly among the urban poor.
more
Breakthrough ACTION a développé des affiches, des spots audiovisuels et des bannières pour le lancement du vaccin antipaludique R21/Matrix M en la République du Congo. Ces messages visent à promouvoir l’acceptation et l’utilisation du vaccin contre le paludisme. Cet effort a impliqué une c...ollaboration avec des experts techniques de divers partenaires et des membres de la Task-Force Communication Paludisme, le Programme National de Lutte contre le Paludisme, ainsi qu’avec le Programme Elargi de Vaccination.
Accessed on 15/07/2025.
more
El documento proporciona información básica sobre la malaria (paludismo), una enfermedad grave causada por un parásito que se transmite a través de la picadura de ciertos mosquitos, describe sus síntomas principales, cómo se diagnostica y trata, y ofrece recomendaciones de prevención, especia...lmente para quienes viajan a zonas donde la enfermedad es común.
more
The two-year impact report for the Access to COVID-19 Tools (ACT) Accelerator details impact, case studies and timelines of key milestones for the Diagnostics, Therapeutics and Vaccines pillars, as well as the Health Systems and Response Connector.
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.
The report presents current information (updated to September 2015) on candidate vaccines, therapies and medical devices for Ebola and gives an overview of completed and on-going trials.